ARCHIVES

Letter to the Editor: Could Managed care Cause Drop In Accrual In Suramin Trial?

This article is from The Cancer Letter archive.

Vol. 22 No. 01 | January 5, 1996

Download PDF Visit The Full Archive

Related Articles

MGMT Gene Can Determine Disease Aggressiveness

June 24, 2011

NCI Proposes Consolidation of Nine Cooperative Groups to Four

December 17, 2010

FDA Didn’t Punish Duke for Failing To Seek Proper Regulatory Clearance for Three Trials

January 27, 2012

Breast Cancer Low Fat Investigators to Seek R01 Funds for New Compliance, Biochemical Studies

April 25, 1986

FDA Approves Tamoxifen For DCIS Folowing Breast Surgery And Radiation.

July 28, 2000

Drugs and Targets: Akynzeo approved for chemotherapy-related nausea

October 10, 2014